1058 GMT - EssilorLuxottica's purchase of Cellview Imaging marks the second acquisition in ophthalmology diagnostics for the European eyecare giant as it pushes into this and other subcategories, RBC Capital Markets' Piral Dadhania says in a note. The Ray-Ban maker said it is buying Canadian startup Cellview, which offers diagnostics via retinal imaging, for an undisclosed sum. The deal follows EssilorLuxottica's July acquisition of Heidelberg Engineering, another ophthalmology diagnostics company, and strengthens its offering, RBC says. EssilorLuxottica is pursuing a structural expansion into selective ophthalmology subcategories, with a move into diagnostics already in progress and potentially in cataracts and contact lenses down the line, the analyst says. Shares rise 1.1%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
February 11, 2025 05:58 ET (10:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.